dc.contributor.author
Ramírez, Julio
dc.contributor.author
Ruiz-Esquide Torino, Virginia
dc.contributor.author
Pomés, Isaac
dc.contributor.author
Celis, Raquel
dc.contributor.author
Cuervo, Andrea
dc.contributor.author
Hernández Miguel, María Victoria
dc.contributor.author
Pomés Talló, Jaume
dc.contributor.author
Pablos, José L.
dc.contributor.author
Sanmartí Sala, Raimon
dc.contributor.author
Cañete Crespillo, Juan D.
dc.date.issued
2018-02-23T11:30:05Z
dc.date.issued
2018-02-23T11:30:05Z
dc.date.issued
2014-01-08
dc.date.issued
2018-02-23T11:30:05Z
dc.identifier
https://hdl.handle.net/2445/120172
dc.description.abstract
INTRODUCTION: The aim of this study was to identify and characterize subclinical synovitis in patients with rheumatoid arthritis (RA) in clinical remission using power Doppler ultrasound (PDUS) and serum levels of biomarkers of inflammation and/or angiogenesis. METHODS: We selected patients with RA in clinical remission defined as a Disease activity score of 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) <2.6 for more than six months tested by two independent rheumatologists. Clinical, epidemiological, demographic and serological data were analyzed. PDUS of knees and hands was performed by a sonographer. Synovial hypertrophy (SH) and PDUS signal were scored (grades 0 to 3). SH ≥2 and a PDUS signal was classified as active synovitis. Serum levels of biomarkers of inflammation/angiogenesis were determined by Quantibody Human Array. RESULTS: This study included 55 patients, of whom 25 (45.4%) met criteria for ultrasound-defined active synovitis. Patients with active synovitis had higher DAS28-C reactive protein (P = 0.023), DAS28-ESR (P = 0.06), simplified disease activity score, SDAI (P = 0.064), and only 12% were taking oral glucocorticoids (≤5 mg/day) compared with 40% of patients without active synovitis (P = 0.044). Patients with synovitis also had significantly higher serum levels of the angiogenic biomarkers angiopoietin-2 (P = 0.038), vascular endothelial growth factor-D (P = 0.018), placental growth factor (P = 0.043), stromal cell-derived factor-1 (P = 0.035), matrix metallopeptidase-2 (P = 0.027) and basic fibroblast growth factor (bFGF) (P = 0.007), but not of pro-inflammatory cytokines. CONCLUSIONS: Nearly half of the patients with RA in clinical remission had ultrasound-defined active synovitis, higher disease activity and less frequent oral glucocorticoid consumption than patients without active synovitis. This clinical situation was associated with a specific biological profile characterized by an excess of angiogenic mediators rather than persistent proinflammatory cytokine responses.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
BioMed Central
dc.relation
Reproducció del document publicat a: https://doi.org/10.1186/ar4431
dc.relation
Arthritis Research & Therapy, 2014, vol. 16, num. 1, p. R5
dc.relation
https://doi.org/10.1186/ar4431
dc.rights
cc-by (c) Ramírez, Julio et al., 2014
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Artritis reumatoide
dc.subject
Malalties de les articulacions
dc.subject
Marcadors bioquímics
dc.subject
Assaigs clínics
dc.subject
Rheumatoid arthritis
dc.subject
Joints diseases
dc.subject
Biochemical markers
dc.subject
Clinical trials
dc.title
Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion